Nagesh

Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair

Retrieved on: 
Wednesday, January 4, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IPO, Babson College, Vesicle (biology and chemistry), Harvard Medical School, California Institute for Quantitative Biosciences, Therapy, Vertex, Corporation, Interim, Alnylam Pharmaceuticals, Vice president, MBA, Acquisition, Ávila, University, University of Colorado Denver School of Public Affairs, Exo, Nagesh, Doctor of Philosophy, Chemistry, Neuroscience, Biology

Exo Therapeutics, Inc. , a company pioneering the use of enzymatic exosites to address intractable drug targets, today announced the appointment of Nagesh Mahanthappa, PhD, to Executive Chair.

Key Points: 
  • Exo Therapeutics, Inc. , a company pioneering the use of enzymatic exosites to address intractable drug targets, today announced the appointment of Nagesh Mahanthappa, PhD, to Executive Chair.
  • “The ExoSight™ platform has tremendous potential to be applied across a wide range of diseases and therapeutic targets,” said Dr. Mahanthappa.
  • “It’s an honor to join Exo as Executive Chair at this exciting time and guide the advancement of our best- and first-in-class programs towards the clinic.”
    Dr. Mahanthappa has served on Exo’s Board of Directors since March 2021 before being appointed Executive Chair.
  • “We are thrilled that Nagesh is stepping into the role of Executive Chair at this important time in the company’s development,” said Dorothy Lou Bailey, COO and Interim President at Exo.

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, Risk, SMA, FAQ, Human, COVID-19, Nagesh, Twitter, Fibrosis, Research, Securities Act of 1933, Â, Hoechst AG, Temple University Hospital, LinkedIn, Company, Part, Review, Private Securities Litigation Reform Act, Spinal muscular atrophy, Social media, Growth, Investor, Temple University School of Medicine, U.S. Securities and Exchange Commission, Patient, File, Clinical trial, Cancer, CEO, IQVIA, Interim, Acceleron Pharma, Internal medicine, Board of directors, Leadership, Intellectual property, NASDAQ, Rock, Board, Security (finance), R, Multimedia, Celgene, Merck, Neuromuscular Disorders, Public health, Management, Pharmaceutical industry, Director, Gongshi

He most recently served as Executive Vice President, Research and Development at Acceleron Pharma, which was acquired by Merck in 2021.

Key Points: 
  • He most recently served as Executive Vice President, Research and Development at Acceleron Pharma, which was acquired by Merck in 2021.
  • Jay is an exceptional executive leader with a track record of success that spans several decades in the biopharmaceutical industry.
  • I would like to thank Nagesh for his remarkable leadership and commitment to Scholar Rock during his 10-year tenure at the company.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc. REBLOZYL is a registered trademark of Celgene Corporation.

Shrinath Bolloju, Managing Director, CitiBank, India Joins KGiSL

Retrieved on: 
Wednesday, July 14, 2021
Articles, Corporate governance, Business, Economy, Chief strategy officer, CSO, Chief operating officer, Nagesh

Shrinath Bolloju joins KGiSL as Chief Strategy Officer, Ramesh Nagesh as Chief Operating Officer, and Noor Hayati Ahmad as Senior Vice President & Country Head, KGiSL Singapore.

Key Points: 
  • Shrinath Bolloju joins KGiSL as Chief Strategy Officer, Ramesh Nagesh as Chief Operating Officer, and Noor Hayati Ahmad as Senior Vice President & Country Head, KGiSL Singapore.
  • An accomplished business leader with close to three decades of experience in financial services, Shrinath Bolloju joins KGiSL as Chief Strategy Officer (CSO).
  • As CSO at KGiSL, Shrinath will be based out of Mumbai, India.
  • Ramesh Nagesh joins KGiSL as Chief Operating Officer (COO) and will be based in Bangalore, India.